ZYDUSLIFEstockZydus Lifesciences Ltd
₹1,064
▼-1.34%
Open
₹1,058.4
High
₹1,078.1
Low
₹1,054.2
Volume
2.57M
Price chart
Daily close · downsampled 5-year history
2021-06-21 · ₹629.42026-06-18 · ₹1,074.3
Instrument details
- MB Code
- MBEQU5613
- Type
- stock
- ISIN
- INE010B01027
- BSE
- 532321
- Industry
- Pharmaceuticals & Biotechnology
Latest earnings
Q4FY26 declared
- Quarter
- Mar 2026
- Revenue
- 7587 Cr
- Net profit
- 1341.3 Cr
- EPS
- 12.65
- YoY revenue
- +16.22%
Price returns
Historical performance
- 1 day
- +1.21%
- 1 month
- +5.43%
- 3 months
- +20.63%
- 1 year
- +12.16%
- 3 years
- +93.79%
- 5 years
- +73.22%
Technicals
Indicator consensus
Bullish
23
Neutral
8
Bearish
15
RSI 41.36(Neutral)
Company documents
Annual reports, concalls, presentations
Concall transcripts
40Investor presentations
78Corporate announcements
644Corporate timeline
Price chart events · 1 year
Dividend
2025-07-25
{"amount":11}
Buyback
2026-05-29
{"maxBuyBackPrice":1150,"totalAggregatedAmount":1100,"offerType":"Tender Offer"}
Buyback
2026-05-29
{"maxBuyBackPrice":1260,"totalAggregatedAmount":1100,"offerType":"Tender Offer"}
Earnings
2026-05-19
{"actualRevenue":75870000000,"estimateRevenue":70742000000,"revenueSurprise":5128000000,"revenueSurprisePercent":7.248876198015323,"actualEPS":16.6,"estimateEPS":8.608028000000001,"surprise":7.991972000000001,"surprisePercent":92.84323889281029}
Earnings
2026-02-09
{"actualRevenue":68645000000,"estimateRevenue":62377000000,"revenueSurprise":6268000000,"revenueSurprisePercent":10.04857559677445,"actualEPS":11.02,"estimateEPS":9.0772033,"surprise":1.942796699999999,"surprisePercent":21.40303170250686}
Earnings
2025-08-12
{"actualRevenue":65737000000,"estimateRevenue":65160000000,"revenueSurprise":577000000,"revenueSurprisePercent":0.8855125844076119,"actualEPS":14.58,"estimateEPS":10.706,"surprise":3.874000000000001,"surprisePercent":36.18531664487204}
Earnings
2025-11-06
{"actualRevenue":61232000000,"estimateRevenue":59950000000,"revenueSurprise":1282000000,"revenueSurprisePercent":2.138448707256047,"actualEPS":12.85,"estimateEPS":13.192115,"surprise":-0.3421150000000015,"surprisePercent":-2.593329424432712}
News
2026-05-27
{"description":"Zydus Lifesciences' arm Zydus Therapeutics got FDA priority review for saroglitazar in PBC; the PDUFA target action date is November 27, 2026. The company also posted strong Q4 net profit and revenue growth.","url":"https://www.cnbctv18.com/market/stocks/zydus-lifesciences-share-price-arm-secures-us-fda-priority-review-for-liver-disease-drug-application-ws-l-19914637.htm","sentiment":"Positive","domain":"CNBCTV18"}
News
2026-05-20
{"description":"Zydus Lifesciences jumped over 6% to a life high after Q4FY26 results showed 16% revenue growth, 8.7% higher net profit and brokerages turned bullish on further upside.","url":"https://www.msn.com/en-in/money/markets/zydus-lifesciences-share-price-spikes-over-6-hits-life-high-brokerages-see-upside-post-q4fy26-revenue-surges-16/ar-AA23C94M?ocid=BingNewsVerp","sentiment":"Positive","domain":"ET Now on MSN"}
News
2026-05-19
{"description":"Zydus Lifesciences beat Q4FY26 estimates, with revenue up 16% to ₹7,587 crore and adjusted net profit up 15%. It also guided for high-teens revenue growth in FY27.","url":"https://www.livemint.com/companies/company-results/zydus-lifesciences-q4-results-fy27-growth-strategy-specialty-pharma-acquisitions-11779195975522.html","sentiment":"Positive","domain":"Mint"}